Results 81 to 90 of about 53,280 (246)

Coverage Generosity of Novel Antirheumatic Drugs in Medicare Advantage and Stand‐Alone Part D Plans

Arthritis &Rheumatology, EarlyView.
Objective We examine coverage of self‐administered disease‐modifying antirheumatic drugs (DMARDs) in Medicare Part D. Methods Using 2022–2026 Part D formulary data, we assessed coverage of the following DMARD classes that treat relapsed rheumatoid arthritis (RA): tumor necrosis factor (TNF) inhibitors, T cell costimulatory modulator, interleukin‐6 (IL ...
Youngmin Kwon, Robert W. Corty, Stacie B. Dusetzina   +2 more
wiley   +1 more source

Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice

Arthritis Research & Therapy, 2019
Background Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a sometimes life-threatening complication in RA patients. SKG mice develop not only arthritis but also an ILD resembling RA-ILD.
Sho Sendo, Jun Saegusa, Hirotaka Yamada, Keisuke Nishimura, Akio Morinobu   +4 more
doaj   +1 more source

PMS48 Cost-Effectiveness of Tocilizumab for The Management of Inadequately Responding Rheumatoid Arthritis Patients [PDF]

, 2003
Weiner, LawrencePrimer pla de l'obra. Tres grans paral·lelepípedes de formigó, amb aparença de sarcòfags.Repartits al llarg de l'avinguda.
Hansen, R.N., Best, J.H., Sullivan, S.D., Carlson, J.J.   +3 more
core   +1 more source

Facilitating Expedited Drug Approval—the Past, Present, and Future of Clinical Trials for Pediatric Rheumatic Disease

Arthritis Care &Research, EarlyView.
Pamela F. Weiss, Hermine I. Brunner
wiley   +1 more source

Patient‐ and Clinician‐Related Factors Associated With the Reduction in Opioid Use Among Adults With Chronic Non‐Cancer Pain: A Systematic Review

Clinical Pharmacology &Therapeutics, EarlyView.
Despite known risks, opioids are widely used for chronic non‐cancer pain (CNCP). Clinical guidelines now recommend deprescribing, but factors predicting success are poorly understood. This systematic review aimed to identify clinician and patient factors associated with attaining successful opioid dose reduction or discontinuation in adults with CNCP ...
Alessandra C. Marcelo, Sarah N. Hilmer, David J. Hunter, Stephanie Mathieson, Riyaas Mohamed, Leo Li, Natalie Fung, Anthony Yue, Manuela L. Ferreira   +8 more
wiley   +1 more source

Advances in the treatment of polyarticular juvenile idiopathic arthritis [PDF]

, 2015
Purpose of review: To review recent advances in the management strategies of polyarticular course juvenile idiopathic arthritis (JIA) and identify unanswered questions and avenues for further research.
Webb, K, Wedderburn, LR
core   +1 more source

Concomitant 5‐Aminosalicylic Acid Does Not Affect the Efficacy of Janus Kinase Inhibitors in Ulcerative Colitis

Clinical Pharmacology &Therapeutics, EarlyView.
We evaluated whether concomitant 5‐aminosalicylic acid (5‐ASA) influences clinical remission in patients with ulcerative colitis (UC) receiving Janus kinase inhibitors (JAKi). In this retrospective, multicenter cohort study, UC patients receiving tofacitinib (n = 181), upadacitinib (n = 313), or filgotinib (n = 139) were included.
Antonio Tursi, Andrea Pasta, Walter Elisei, Brigida Barberio, Giammarco Mocci, Giovanni Maconi, Antonietta Gerarda Gravina, Raffaele Pellegrino, Giorgia Bodini, Edoardo Vincenzo Savarino, Alfredo Papa, Italian Network for Inflammatory Bowel Diseases (IN‐IBD), Davide G. Ribaldone, Antonio Ferronato, Greta Lorenzon, Davide Checchin, Francesca Lambroglia, Francesco Ferrara, Carla Felice, Giovanni Cataletti, Giorgia Bodini, Andrea Pasta, Giovanni Aragona, Patrizia Perazzo, Federica Gaiani, Stefano Kayali, Fabio Cortellini, Francesco Costa, Lorenzo Bertani, Antonella Scarcelli, Mariaelena Serio, Emanuele Bendia, Laura Bolognini, Daniele Balducci, Claudia Quatraccioni, Francesco Martini, Michele Montori, Simona Piergallini, Francesca Maria Onidi, Paolo Usai Satta, Giorgia Orrù, Raffaele Colucci, Francesco Bachetti, Gabrio Bassotti, Elisabetta Antonelli, Costantino Zampaletta, Giulia Rocco, Carlotta Sacchi, Franco Scaldaferri, Daniele Napolitano, Roberto Faggiani, Michela Di Fonzo, Rita Monterubbianesi, Cristiano Pagnini, Maria Giovanna Graziani, Maria Carla Di Paolo, Roberta Pica, Maddalena Zippi, Andrea Cocco, Claudio Cassieri, Roberto Lorenzetti, Gian Marco Giorgetti, Valeria Clemente, Patrizio Scarozza, Girolamo Bevevino, Giulia Zerboni, Federico Iacopini, Giacomo Forti, Laurino Grossi, Serafina Fiorella, Giovanni Lombardi, Marta Patturelli, Giuliana Vespere, Silvia Sedda, Vittorio D’Onofrio, Leonardo De Luca, Caterina Mucherino, Elvira D’Antonio, Laura Montesano, Pietro Capone, Guido Daniele Villani, Antonio Cuomo, Laura Donnarumma, Nicola Della Valle, Giuseppe Pranzo, Paolo Tonti, Viviana Neve, Libera Fanigliulo, Leonardo Allegretta, Alessia Immacolata Cazzato, Stefano Scorza, Manuela Marzo, Ileana Luppino, Francesco Luzza, Rocco Spagnuolo, Stefano Rodinò, Ladislava Sebkova, Antonio De Medici, Domenico Catarella, Dario D’Agostino, Elisabetta Di Bartolo   +100 more
wiley   +1 more source

Carbon Footprint of Antibody‐Based Drugs and Biologics Using Hybrid Life Cycle Assessment

Clinical Pharmacology &Therapeutics, EarlyView.
Life cycle assessment of monoclonal antibodies. Biological engineering has emerged since the 1980s as one of the most efficient technologies to develop new medicines. The monoclonal antibody platform is the most widely used, representing about 15–20% of drug sales.
Sébastien Taillemite, Martin Fenelon, Marc Scherlinger, Max Piffoux   +3 more
wiley   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Patterns of Tumor Necrosis Factor Inhibitor (TNFi) Biosimilar Use Across United States Rheumatology Practices. [PDF]

, 2020
ObjectiveIt is unclear if biosimilars of biologics for inflammatory arthritis are realizing their promise to increase competition and improve accessibility.
Bansback, Nick, Curtis, Jeffrey R, Evans, Michael, He, Zeling, Huang, Jie, Johansson, Tracy, Liao, Katherine P, Michaud, Kaleb, Schmajuk, Gabriela   +8 more
core   +1 more source